Silver did you mean toc tic or #$%$ toc? lol I'll take it either way.
Thanks wook, looking forward to some exciting times with PPHM
•Beth Israel Deaconess Medical Center
Location: Boston, Massachusetts 02215
•Dartmouth-Hitchcock Medical Center
Location: Lebanon, New Hampshire 03756
•Arena Oncology Associates, PC
Location: Lake Success, New York 11042
•St. Luke's Cancer Center
Location: Bethlehem, Pennsylvania 18015
•Lynchburg Hematology-Oncology Clinic
Location: Lynchburg, Virginia 24501
•Leo W. Jenkins Cancer Center - East Carolina University
Location: Greenville, North Carolina 27834
•The Cancer Center at DeKalb Medical
Location: Decatur, Georgia 30033
•Northeast Georgia Medical Center
Location: Gainesville, Georgia 30501
•Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Location: Savannah, Georgia 31405
•John B. Amos Cancer Center
Location: Columbus, Georgia 31904
•Lynn Cancer Institute
Location: Boca Raton, Florida 33486
•Joliet Oncology-Hematology Associates, Ltd.
Location: Joliet, Illinois 60435
•Vasicek Cancer Center at Scott & White Memorial Hospital
Location: Temple, Texas 76508
•Ironwood Cancer & Research Centers
Location: Chandler, Arizona 85224
•Moores UCSD Cancer Center
Location: La Jolla, California 92093
State: New Hampshire
Zip Code: 03756
Conditions: Metastatic Pancreatic Cancer
Purpose: The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
Study Summary: This is prospective, randomized, open-label, multicenter, phase 2 study of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer.
Criteria: Inclusion Criteria: - Written informed consent has been obtained. - Adults of 18 years of age or older with a life expectancy of at least 3 months. - Patients with histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas. - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. - Adequate hematologic function (ANC ≥ 1,500 cells/µL; hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL). - Adequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min). - Adequate hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN); ALT and AST may be 1 year postmenopausal). - All patients of reproductive potential must agree to use an approved form of contraception (as determined by the investigator). Exclusion Criteria: - Neuroendocrine tumors (carcinoid, islet cell cancer) of the pancreas. - NYHA Class III or IV, cardiac function, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease. - Known brain, leptomeningeal or epidural metastases. - Radiation therapy within 7 days of Study Day 1, lack of recovery from previous therapeutic radiation, or planned radiation therapy during the study period. - Previously received any systemic treatment for pancreatic cancer, including prior neoadjuvant or adjuvant chemotherapy for lower stage disease. - Previously malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years. - Severe chronic obstructive or other pulmonary disease with hypoxemia. - Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery. - Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. - Ongoing therapy with oral or parenteral anticoagulants; patients on low-dose anticoagulants to maintain patency of lines are eligible. - Venous thromboembolic events (e.g. deep vein thrombosis or pulmonary embolism) within 6 months of screening. - QTC interval of 470 ms on screening. - Long QT syndrome or family history of sudden cardiac death in young family members. - Subjects who participated in an investigational drug or device study within 28 days prior to study entry. - Known active infection with HIV, hepatitis B, or hepatitis C. - Females who are pregnant or breast-feeding. - Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. - Unwillingness or inability to comply with the study protocol for any reason.
NCT ID: NCT01272791
Primary Contact: Study Chair Thomas Sklenar
Lebanon, New Hampshire 03756
Clinical Source: ClinicalTrials.gov
Date Processed: February 09, 2013
Information obtained from ClinicalTrials.gov on February 07, 2013. Whatever information they are referring to was obtained on February 7th, 2013. I found this by putting this phrase in googles search engine; "Dartmouth Hitchcock Pancreatic patients bavituximab" Here's some other interesting stuff: Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer,
Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its lung cancer drug, Peregrine stock has massive upside.
Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012.
I think their one year target estimate is low but what the heck
Who do you believe the bashers or JMP Securities & Roth Capital?
JMP SECURITIES (Strong Buy)
ROTH CAPITAL PA (Strong Buy)
Additionally, another solution may be found with regards to curing the infection. A cross anti-viral drug called Bavituximab has already proved successful in effectively treating mice and guinea pigs infected with various enveloped viruses. Herpes viruses fall within this category, and it is thought that the virus might be eradicated from the body using this drug. The drug works by binding onto infected cells, including cancer cells, and signaling to the immune system to come and destroy the problem cells. This is a novel technique in medicine and is eagerly anticipated since it is believed that cross-protection against latent viruses such as herpes simplex, Epstein-Barr, &c., will make an important contribution to improving public health.
PPHM is alive and well
Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
Based on a pre-defined weighted trend formula for chart analysis, PPHM scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Friday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, November 26th
+30 New 3 Month High on July 3
+100 Total Score
We are positive on Seattle Genetics’ efforts to penetrate new markets. In Canada, Adcetris is the first in a new class of antibody-drug conjugates (ADCs) to be approved. Adcetris’ revenues for the nine months ending Sep 30, 2012 were $102.8 million.
Seattle Genetics carries a Zacks Rank #4 (Sell). Right now Peregrine Pharmaceuticals, Inc. (PPHM), Valeant Pharmaceuticals (VRX) and Targacept, Inc. (TRGT) look more attractive with a Zacks Rank #1 (Strong Buy).
Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). Adcetris has been approved under Health Canada's Notice of Compliance with conditions (NOC/c) for the treatment of patients with Hodgkins lymphoma (HL) after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT.
Adcetris was also approved for the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen.
For similar indications, Adcetris was approved by the US Food and Drug Administration (:FDA) in Aug 2011 and in the EU in Oct 2012.
The NOC/c requires Seattle Genetics to conduct clinical trials to confirm the anticipated clinical benefit of Adcetris. Seattle Genetics is currently enrolling patients for two confirmatory phase III studies evaluating the drug for the front-line treatment of HL and mature T-cell lymphoma (:MTCL), including sALCL.
Meanwhile, in Jan 2013, a global phase III study (ECHELON-2) was initiated on Adcetris. In this study, Adcetris plus chemotherapy will be evaluated for the front-line treatment of CD30-positive MTCL including patients with sALCL and other types of peripheral T-cell lymphomas.
Conclusions: Bavituximab, a unique phosphatidylserine targeting monoclonal antibody which is capable of inducing immune enhancement and immune cell-mediated destruction of tumor vasculature appears to be safe and well tolerated when given in combination with paclitaxel and carboplatin and has produced a promising 60% overall response rate in an initial group of subjects using RECIST criteria for locally advanced or metastatic breast cancer.